Detecting mild COPD: Don't waste resources

Primary Care Respiratory Journal

Volumn 20, Issue 1, 2011, Pages 6-8

  Enright, Paul ^a   White, Patrick ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; PLACEBO; TIOTROPIUM BROMIDE;

ABDOMINAL OBESITY; AIRWAY OBSTRUCTION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DYSPNEA; EDITORIAL; EXERCISE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITAL ADMISSION; HUMAN; INTERVENTION STUDY; LUNG FUNCTION; MEDICAL LITERATURE; MEDICAL SOCIETY; PATIENT CARE; PATIENT COUNSELING; PRACTICE GUIDELINE; PREDICTION; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK ASSESSMENT; SMOKING CESSATION; SPIROMETRY; SYMPTOMATOLOGY;

EID: 80053053485     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2011.00004     Document Type: Editorial

References (29)

1. Price D, Freeman D, Cleland J, Kaplan A, Cerasoli F. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J 2011;20(1):15-22. http://dx.doi.org/10.4104/pcrj.2010.00060
2. Buffels J, Degryse J, Decramer M, Heyrman J. Spirometry and smoking cessation advice in general practice: a randomised clinical trial. Respir Med 2006;100(11):2012-2017. http://dx.doi.org/10.1016/j.rmed.2006.02.014
3. Wilt TJ, Niewoehner D, Kane RL, MacDonald R, Joseph AM. Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res 2007;9(1):21-32. http://dx.doi.org/10.1080/14622200601078509
4. Lin KW. Screening for chronic obstructive pulmonary disease using spirometry. Am Fam Physician 2009;80(8):861.
5. Kotz D, Wesseling G, Huibers MJ, van Schayck OC. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 2009;33 (4):754-762. http://dx.doi.org/10.1183/09031936.00116308
6. Górecka D, Bednarek M, Nowifski A, PuÊcifska E, Goljan-Geremek A, Zielifski J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003;123(6):1916-1923. http://dx.doi.org/10.1378/chest.123.6.1916
7. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006;61(10):869-873. http://dx.doi.org/10.1136/thx.2006.059071
8. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate telling patients their lung age: the Step2quit randomized controlled trial. BMJ 2008; 336:598-600.
9. Lipkus IM, Prokhorov AV. The effects of providing lung age and respiratory symptoms feedback on community college smokers' perceived smoking-related health risks, worries and desire to quit. Addictive Behav 2007;32:516-532. http://dx.doi.org/10.1016/j.addbeh.2006.05.018
10. Bize R, Burnand B, Mueller Y, Cornuz J. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2005;(4):CD004705.
11. vanSchayck OC, Pinnock H, Ostrem A, et al. IPCRG Consensus statement: tackling the smoking epidemic - practical guidance for primary care. Prim Care Respir J 2008;17(3):185-193. http://dx.doi.org/10.3132/pcrj.2008.00060
12. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161(2 Pt 1):381-390.
13. Pinto-Plata VM, Celli-Cruz RA, Vassaux C, et al. Differences in cardiopulmonary exercise test results by American Thoracic Society/European Respiratory Society-Global Initiative for Chronic Obstructive Lung Disease stage categories and gender. Chest 2007;132(4):1204-1211. http://dx.doi.org/10.1378/chest.07-0593
14. Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80 percent of predicted and fixed thresholds misclassifies over 20% of patients. Chest 2010;Jun 3. [Epub ahead of print]
15. Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med 2009;179(6):509-516. http://dx.doi.org/10.1164/rccm.200807-1195OC
16. Vestbo J, Rennard S. Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. Am J Respir Crit Care Med 2010;182(7):863-864. http://dx.doi.org/10.1164/rccm.201004-0602ED
17. Wilson JMG and Jungner G. Principles and Practice of Screening for Disease, WHO 1968
18. O'Reilly J, Jones MM, Parnham J, Lovibond K, Rudolf M; Guideline Development Group. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010;340:c3134.
19. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932-946. http://dx.doi.org/10.1183/09031936.04.00014304
20. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease -2008 update - highlights for primary care. Can Respir J 2008;15 Suppl A:1A-8A.
21. Anthonisen NR. Lessons from the Lung Health Study. Proc Am Thorac Soc 2004; 1(2):143-145. http://dx.doi.org/10.1513/pats.2306033
22. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178(4):332-338. http://dx.doi.org/10.1164/rccm.200712-1869OC
23. Tashkin DP, Celli B, Senn S, et al. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15):1543-1554. http://dx.doi.org/10.1056/NEJMoa0805800
24. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10:59-68.
25. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374(9696):1171-1178. http://dx.doi.org/10.1016/S0140-6736(09)61298-8
26. Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study. Respir Res 2007;8:45-55. http://dx.doi.org/10.1186/1465-9921-8-45
27. Jones PW. St. George's Respiratory Questionnaire: MCID. J of Chronic Obstructive Pulmonary Disease 2005;2:75-79. http://dx.doi.org/10.1081/COPD-200050513
28. Kainu A, Lindqvist A, Sarna S, Lundbäck B, Sovijärvi A. FEV1 response to bronchodilation in an adult urban population. Chest 2008;134(2):387-393. http://dx.doi.org/10.1378/chest.07-2207
29. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142(4):233-239.